Printer Friendly

THERION ACQUIRES EXCLUSIVE LICENSE TO NOVEL POX VECTOR TECHNOLOGY FOR HUMAN VACCINES, FORMS RESEARCH COLLABORATION WITH UNIV. OF FLORIDA

 CAMBRIDGE, Mass., July 20 /PRNewswire/ -- Therion Biologics Corporation announced today that it has acquired from the University of Florida Research Foundation, Inc., Gainesville, exclusive worldwide rights to develop and commercialize human vaccines using novel vector systems based on swinepox and entomopox viruses. These vector systems will serve as a basis for developing new human vaccines for preventative and therapeutic use.
 Therion intends to use swinepox as a vector to develop vaccines against human infectious diseases and cancers. Swinepox is an asymptomatic viral disease affecting only pigs. The swinepox virus, which is naturally attenuated and therefore harmless to humans, provides a way to stimulate the immune system without the potential for causing disease.
 "The swinepox and entomopox technologies provide a platform for developing a second generation of live recombinant viral vector products with the potential for enhanced safety and broad immunotherapy applications," commented Dennis Panicali, Ph.D., president and CEO of Therion. "The first product application we plan to explore is in the cancer immunotherapeutic area."
 Under the agreement with the University of Florida, Therion has rights to two families of patents. The first relates to the use of swinepox as a vector, and the second relates to an expression system based on entomopox, which is derived from an insect virus.
 In connection with the agreement, Therion will support additional research in poxvirus vector technology conducted by Richard Moyer, Ph.D., professor and chairman of the Department of Immunology and Medical Microbiology at the University of Florida College of Medicine. Dr. Moyer has pioneered the use of swinepox and entomopox as vectors and protein expression systems.
 Therion Biologics Corporation is engaged in the development of vaccines and immunotherapeutic products for the prevention and treatment of cancers, AIDS and other viral diseases. Therion, founded in 1991, is headquartered in Cambridge, Mass.
 -0- 7/20/93
 /CONTACT: Dennis L. Panicali, Ph.D., president and CEO, Therion Biologics Corp., 617-876-7779; Lynne H. Brum of Feinstein Partners Inc., 617-577-8110/


CO: Therion Biologics Corporation ST: Massachusetts IN: MTC SU: PDT

DJ -- NE004 -- 6558 07/20/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1993
Words:343
Previous Article:STANDARD PACIFIC CORP. REPORTS SECOND QUARTER FINANCIAL RESULTS
Next Article:CHEMDESIGN REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
TARGETED GENETICS LICENSES IN VIVO AAV TECHNOLOGIES FOR HUMAN GENE THERAPY
Therion Biologics Initiates Phase I Trials with Three Melanoma Therapeutics in Collaboration with the National Cancer Institute
Maxygen Announces Issuance of Patent Covering Preparation of Improved Vectors.
Cell Genesys Licenses Lentiviral Gene Delivery Technology to Invitrogen For the Research Market.
Cell Genesys Licenses Lentiviral Gene Delivery Technology to Invitrogen For the Research Market.
Therion Biologics Corporation Appoints Thomas J. Schuetz, M.D., Ph.D., as Chief Medical Officer.
Therion Biologics Obtains Rights to Biogen Idec LFA-3 Patents.
Therion Biologics obtains rights to Biogen Idec LFA-3.
Researchers Publish Supporting Safety and Anti-tumor Activity of Therion Biologics' CEA-TRICOM(TM) Therapeutic Vaccine in Journal of Clinical...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters